Asunercept
drugOn this page
Also known as APG-101Apg101ApoceptAsinerceptCAN-008
Summary
Asunercept (CHEMBL4297886) is a phase-3 clinical-stage protein; indicated across 3 conditions including severe acute respiratory syndrome and glioblastoma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Protein
- Indications: 3 conditions
- Clinical trials: 6
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4297886 |
| Name | Asunercept |
| Type | Protein |
| Max phase | 3 |
Also known as: APG-101, Apg101, APG101, Apocept, Asinercept, Asunercept, CAN-008, ASUNERCEPT
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| severe acute respiratory syndrome | 3 | MONDO:0005091 | MONDO:0100096 |
| glioblastoma | 2 | MONDO:0018177 | EFO:0000519 |
| myelodysplastic syndrome | 1 | MONDO:0018881 | EFO:0000198 |
Clinical trials
Total trials: 6.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 2 |
| PHASE2/PHASE3 | 1 |
| PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04351724 | PHASE2/PHASE3 | UNKNOWN | Austrian CoronaVirus Adaptive Clinical Trial (COVID-19) |
| NCT05639192 | PHASE3 | TERMINATED | Asunercept for the Treatment of Patients With Moderate to Severe COVID-19 Disease |
| NCT01071837 | PHASE2 | COMPLETED | APG101 in Glioblastoma |
| NCT03158389 | PHASE1/PHASE2 | COMPLETED | NCT Neuro Master Match - N²M² (NOA-20) |
| NCT04535674 | PHASE2 | COMPLETED | Asunercept in Patients With Severe COVID-19 |
| NCT01736436 | PHASE1 | COMPLETED | APG101 in Myelodysplastic Syndrome |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: severe acute respiratory syndrome